{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:54:51Z","timestamp":1772643291888,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01934","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T13:26:15Z","timestamp":1565789175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid"],"prefix":"10.3389","volume":"10","author":[{"given":"Christian D.","family":"Sadik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewan A.","family":"Langan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Gr\u00e4tz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","article-title":"Targeting T cell co-receptors for cancer therapy","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/cup.13044","article-title":"Erythema nodosum-like panniculitis mimicking disease recurrence: a novel toxicity from immune checkpoint blockade therapy-Report of 2 patients","volume":"44","author":"Tetzlaff","year":"2017","journal-title":"J Cutan Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma","volume":"43","author":"Mochel","year":"2016","journal-title":"J Cutan Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1111\/ajd.12488","article-title":"Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma","volume":"58","author":"Parakh","year":"2017","journal-title":"Australas J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jdcr.2017.06.004","article-title":"Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy","volume":"3","author":"Hirotsu","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/CJI.0000000000000191","article-title":"Acute flare of bullous pemphigus with pembrolizumab used for treatment of metastatic urothelial cancer","volume":"41","author":"Garje","year":"2018","journal-title":"J Immunother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/CJI.0000000000000210","article-title":"Bullous pemphigoid-like skin lesions and overt eosinophilia in a patient with melanoma treated with nivolumab: case report and review of the literature","volume":"41","author":"Anastasopoulou","year":"2018","journal-title":"J Immunother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000489661","article-title":"Bullous pemphigoid as an adverse reaction to pembrolizumab: two case reports","volume":"10","author":"Thomsen","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"},{"key":"B14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3389\/fimmu.2017.01752","article-title":"BP180 is critical in the autoimmunity of bullous pemphigoid","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jamadermatol.2017.5465","article-title":"Clinical and immunological profiles of 14 patients with bullous pemphigoid without IgG autoantibodies to the BP180 NC16A domain","volume":"154","author":"Nakama","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0002-9440(10)64772-4","article-title":"The shed ectodomain of collagen XVII\/BP180 is targeted by autoantibodies in different blistering skin diseases","volume":"156","author":"Schumann","year":"2000","journal-title":"Am J Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1523-1747.ep12289703","article-title":"Bullous pemphigoid and linear IgA dermatosis sera recognize a similar 120-kDa keratinocyte collagenous glycoprotein with antigenic cross-reactivity to BP180","volume":"108","author":"Pas","year":"1997","journal-title":"J Invest Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1684\/ejd.2018.3229","article-title":"A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230","volume":"28","author":"Miyashita","year":"2018","journal-title":"Eur J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"832","DOI":"10.2340\/00015555-2400","article-title":"Bullous pemphigoid with immunoglobulin G anti-LAD-1 antibodies without evident erythema and eosinophil infiltration","volume":"96","author":"Ikawa","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1684\/ejd.2014.2322","article-title":"Bullous pemphigoid with IgG anti-LAD-1 antibodies","volume":"24","author":"Matsui","year":"2014","journal-title":"Eur J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1346-8138.2012.01562.x","article-title":"Unilateral bullous pemphigoid without erythema and eosinophil infiltration in a hemiplegic patient","volume":"39","author":"Tsuruta","year":"2012","journal-title":"J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/bjd.16479","article-title":"Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors","volume":"178","author":"Horikawa","year":"2018","journal-title":"Br J Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01934\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T13:26:17Z","timestamp":1565789177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01934\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2019.01934"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01934","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"article-number":"1934"}}